ONCE UPON A FARM PBC PROJECTS FY2026 NET SALES BETWEEN $302 MILLION AND $310 MILLION
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 12 2026
0mins
Should l Buy OFRM?
Source: moomoo
- Financial Guidance: The net sales guidance for FY 2026 is projected to be between $302 million and $310 million.
- Market Outlook: The guidance reflects expectations for the company's performance in the upcoming fiscal year.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OFRM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OFRM
Wall Street analysts forecast OFRM stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 16.010
Low
Averages
High
Current: 16.010
Low
Averages
High
About OFRM
Once Upon a Farm, PBC is engaged in the manufacturing, distribution, marketing and related sale of nutrient-packed, delicious food for babies and kids of on-the-go parents under the brand name, Once Upon a Farm. Its products as offered for Babies, Kids and Toddlers. Its products includemelts, fruit and veggie puffs, frozen meals, refrigerated oat bar, refrigerated pouches and variety packs. Its variety packs include Carter’s Baby & Toddler Favorites, Carter’s Big Kid Favorites, Carter’s Baby & Toddler Snack Sampler, 9ct, Farmer's Finest, Winter Favorites, Refrigerated Bar Sampler, Green Checkered Pouch Cooler 2-Pack, Dairy-Free Smoothie, Fruit & Veggie Puff, Refrigerated Protein Bar, Baby Best Sellers and others. Its meals include Organic Pasta Meals Cauli-fredo & Spinach, Organic Pasta Meals Pomodoro, Veggie Pot Pie, Papaya Sunrise, Banana Berry Acai and others. Its Refrigerated Oat Bars include Apple Cinnamon Oat Bar, Banana Chocolate Oat Bar, Blueberry Oat Bar and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Adobe CEO Resignation Triggers Stock Decline
- Adobe CEO Transition: Adobe's CEO Shantanu Narayen announced his resignation after a successor is named, causing shares to tumble over 5%, despite the company beating first-quarter earnings expectations, indicating market concerns over leadership changes.
- Fertilizer Stocks Retreat: Fertilizer companies' shares fell back due to ongoing disruptions in the Strait of Hormuz, with Intrepid Potash down about 8% and both Mosaic and CF Industries dropping around 4%, reflecting market sensitivity to raw material price fluctuations.
- Ulta Beauty Earnings Miss: Ulta Beauty reported fourth-quarter earnings of $8.01 per share, falling short of the $8.03 expected by analysts, leading to a 12% drop in stock price, despite revenue of $3.9 billion exceeding expectations, highlighting pressures on profitability.
- Once Upon A Farm Performance Decline: Once Upon A Farm reported its first earnings since going public, guiding for 2026 adjusted EBITDA of $2 million to $4 million, significantly lower than $6.6 million in Q4 2025, resulting in an 8% stock drop and raising concerns about future growth prospects.
See More
ONCE UPON A FARM STOCK DROPS BELOW IPO PRICE OF $18 FOR THE FIRST TIME AFTER QUARTERLY RESULTS, FALLING 15.2% TO $17.16
Stock Price Decline: Shares fell 15.2% to $17.16, marking a significant drop below the IPO price of $18.
Quarterly Results Impact: The decline in share price follows the release of quarterly results, indicating investor reaction to the company's performance.
See More
Once Upon A Farm Reports 30.1% Sales Growth in Q4
- Sales Growth Highlight: Once Upon A Farm reported Q4 2025 sales of $64 million, reflecting a 30.1% increase driven by expanded distribution and significant household penetration, showcasing strong brand momentum and consumer trust in its mission-driven approach.
- Gross Margin Improvement: The gross margin for the quarter was 47.7%, up from 46.7% in the prior year, primarily due to lower trade spending and higher average selling prices, enhancing the company's profitability.
- Adjusted EBITDA Surge: Adjusted EBITDA reached $6.6 million, a substantial increase from $2.2 million in the previous year, although partially offset by rising SG&A expenses, indicating significant gross profit growth.
- Negative Market Reaction: Despite GAAP EPS of $0.11 beating consensus estimates, analysts expressed concerns that investors might be disappointed with the reported margin rate, leading to a 19.3% drop in premarket trading to $16.43, below the IPO range of $18.00 to $27.00.
See More
The Oncology Institute Reports Strong Q4 Results, Shares Surge
- Earnings Beat: The Oncology Institute reported a Q4 loss of 6 cents per share, outperforming the analyst consensus estimate of a 9-cent loss, indicating improvements in cost management and operational efficiency, which boosts market confidence in its future profitability.
- Sales Growth: The company achieved quarterly sales of $141.957 million, exceeding the analyst consensus of $139.775 million, reflecting positive progress in market demand and product promotion, thereby strengthening its market position in oncology treatment.
- Stock Surge: Shares of The Oncology Institute jumped 14.7% to $3.01 in pre-market trading, demonstrating a positive investor reaction to the financial results, which may attract more investor interest in its future developments.
- Increased Market Confidence: The better-than-expected performance not only enhances investor confidence but may also prompt analysts to reassess the company's long-term growth potential, potentially influencing future stock price movements and market performance.
See More
Once Upon A Farm Q4 Earnings Beat Expectations
- Strong Quarterly Performance: Once Upon A Farm reported a Q4 GAAP EPS of $0.11, beating expectations by $0.01, indicating ongoing improvements in profitability that bolster investor confidence.
- Significant Revenue Growth: The company achieved Q4 revenue of $64 million, exceeding market expectations by $1 million, reflecting robust consumer demand for its products and further solidifying its market position.
- Net Income Turnaround: Q4 net income reached $22.5 million, a significant recovery from a net loss of $12.3 million in the same period last year, showcasing successful cost control and sales growth, which bodes well for future profitability.
- Impressive Annual Performance: For FY 2025, net sales increased by 53.5% to $240.7 million, and although gross margin slightly decreased to 42.3%, adjusted EBITDA improved from a loss of $3.7 million to a profit of $2.1 million, indicating substantial progress in the company's transformation efforts.
See More
ONCE UPON A FARM PBC REPORTS 30% RISE IN Q4 NET SALES, REACHING $64 MILLION
- Sales Growth: ONCE UPON A FARM reported a 30% increase in net sales, reaching $64 million.
- Financial Performance: The significant growth indicates a strong performance in the company's market presence and product demand.
See More
Adobe CEO Resignation Triggers Stock Decline
- Adobe CEO Transition: Adobe's CEO Shantanu Narayen announced his resignation after a successor is named, causing shares to tumble over 5%, despite the company beating first-quarter earnings expectations, indicating market concerns over leadership changes.
- Fertilizer Stocks Retreat: Fertilizer companies' shares fell back due to ongoing disruptions in the Strait of Hormuz, with Intrepid Potash down about 8% and both Mosaic and CF Industries dropping around 4%, reflecting market sensitivity to raw material price fluctuations.
- Ulta Beauty Earnings Miss: Ulta Beauty reported fourth-quarter earnings of $8.01 per share, falling short of the $8.03 expected by analysts, leading to a 12% drop in stock price, despite revenue of $3.9 billion exceeding expectations, highlighting pressures on profitability.
- Once Upon A Farm Performance Decline: Once Upon A Farm reported its first earnings since going public, guiding for 2026 adjusted EBITDA of $2 million to $4 million, significantly lower than $6.6 million in Q4 2025, resulting in an 8% stock drop and raising concerns about future growth prospects.
See More
ONCE UPON A FARM STOCK DROPS BELOW IPO PRICE OF $18 FOR THE FIRST TIME AFTER QUARTERLY RESULTS, FALLING 15.2% TO $17.16
Stock Price Decline: Shares fell 15.2% to $17.16, marking a significant drop below the IPO price of $18.
Quarterly Results Impact: The decline in share price follows the release of quarterly results, indicating investor reaction to the company's performance.
See More
Once Upon A Farm Reports 30.1% Sales Growth in Q4
- Sales Growth Highlight: Once Upon A Farm reported Q4 2025 sales of $64 million, reflecting a 30.1% increase driven by expanded distribution and significant household penetration, showcasing strong brand momentum and consumer trust in its mission-driven approach.
- Gross Margin Improvement: The gross margin for the quarter was 47.7%, up from 46.7% in the prior year, primarily due to lower trade spending and higher average selling prices, enhancing the company's profitability.
- Adjusted EBITDA Surge: Adjusted EBITDA reached $6.6 million, a substantial increase from $2.2 million in the previous year, although partially offset by rising SG&A expenses, indicating significant gross profit growth.
- Negative Market Reaction: Despite GAAP EPS of $0.11 beating consensus estimates, analysts expressed concerns that investors might be disappointed with the reported margin rate, leading to a 19.3% drop in premarket trading to $16.43, below the IPO range of $18.00 to $27.00.
See More
The Oncology Institute Reports Strong Q4 Results, Shares Surge
- Earnings Beat: The Oncology Institute reported a Q4 loss of 6 cents per share, outperforming the analyst consensus estimate of a 9-cent loss, indicating improvements in cost management and operational efficiency, which boosts market confidence in its future profitability.
- Sales Growth: The company achieved quarterly sales of $141.957 million, exceeding the analyst consensus of $139.775 million, reflecting positive progress in market demand and product promotion, thereby strengthening its market position in oncology treatment.
- Stock Surge: Shares of The Oncology Institute jumped 14.7% to $3.01 in pre-market trading, demonstrating a positive investor reaction to the financial results, which may attract more investor interest in its future developments.
- Increased Market Confidence: The better-than-expected performance not only enhances investor confidence but may also prompt analysts to reassess the company's long-term growth potential, potentially influencing future stock price movements and market performance.
See More
Once Upon A Farm Q4 Earnings Beat Expectations
- Strong Quarterly Performance: Once Upon A Farm reported a Q4 GAAP EPS of $0.11, beating expectations by $0.01, indicating ongoing improvements in profitability that bolster investor confidence.
- Significant Revenue Growth: The company achieved Q4 revenue of $64 million, exceeding market expectations by $1 million, reflecting robust consumer demand for its products and further solidifying its market position.
- Net Income Turnaround: Q4 net income reached $22.5 million, a significant recovery from a net loss of $12.3 million in the same period last year, showcasing successful cost control and sales growth, which bodes well for future profitability.
- Impressive Annual Performance: For FY 2025, net sales increased by 53.5% to $240.7 million, and although gross margin slightly decreased to 42.3%, adjusted EBITDA improved from a loss of $3.7 million to a profit of $2.1 million, indicating substantial progress in the company's transformation efforts.
See More
ONCE UPON A FARM PBC REPORTS 30% RISE IN Q4 NET SALES, REACHING $64 MILLION
- Sales Growth: ONCE UPON A FARM reported a 30% increase in net sales, reaching $64 million.
- Financial Performance: The significant growth indicates a strong performance in the company's market presence and product demand.
See More
